1. 369TiPPATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC). (23rd October 2018) Authors: Loibl, S; Metzger, O; Mandrekar, S J; Mundhenke, C; Seiler, S; Valagussa, P; DeMichele, A; Lim, E; Tripathy, D; Winer, E P; Huang, C; Carey, L; Francis, P; Miller, K D; Goetz, M P; Prat, A; Loi, S; Krop, I; Gianni, L; Ciruelos, E M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. LBA2_PROverall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Analyses from PALOMA-3. (23rd October 2018) Authors: Cristofanilli, M; Slamon, D J; Ro, J; Bondarenko, I; Im, S-A; Masuda, N; Colleoni, M; DeMichele, A; Loi, S; Verma, S; Iwata, H; Harbeck, N; Loibl, S; André, F; Puyana Theall, K; Huang, X; Giorgetti, C; Huang Bartlett, C; Turner, N C Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗